#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA663133	B	Binding energy to Streptococcus faecium dihydrofolate reductase	Enterococcus faecium	68	ALA1122106	single protein format	Scientific Literature
2.	ALA663137	B	Binding energy against Streptococcus faecium dihydrofolate reductase	Enterococcus faecium	68	ALA1121631	single protein format	Scientific Literature
3.	ALA666235	B	The concentration required to inhibit dihydrofolate reductase in rat liver		107	ALA1122689	tissue-based format	Scientific Literature
4.	ALA666238	B	Concentration required for inhibition of rat liver dihydrofolate reductase (DHFR)		103	ALA1122259	assay format	Scientific Literature
5.	ALA1054500	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM	Plasmodium falciparum	13,467	ALA1157539	organism-based format	GSK Malaria Screening
6.	ALA1054501	F	GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM	Plasmodium falciparum	13,467	ALA1157539	organism-based format	GSK Malaria Screening
7.	ALA1054502	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM	Plasmodium falciparum	13,467	ALA1157539	organism-based format	GSK Malaria Screening
8.	ALA1054503	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth.	Plasmodium falciparum	13,467	ALA1157539	organism-based format	GSK Malaria Screening
9.	ALA1054504	F	GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM.	Homo sapiens	13,467	ALA1157539	cell-based format	GSK Malaria Screening
10.	ALA1054505	F	GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested		13,467	ALA1157539	assay format	GSK Malaria Screening
11.	ALA3259106	F	Antimalarial activity against Plasmodium gallinaceum infected in mouse assessed as quinine equivalent to dose required to suppress parasitemia by 75% compound treated through gavage for 3 days	Plasmodium gallinaceum	8	ALA3244272	organism-based format	Scientific Literature
12.	ALA3259108	F	Antimalarial activity against Plasmodium gallinaceum parent strain infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days	Plasmodium gallinaceum	8	ALA3244272	organism-based format	Scientific Literature
13.	ALA3252246	F	Antimalarial activity against chloroquine-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days	Plasmodium gallinaceum	8	ALA3244272	organism-based format	Scientific Literature
14.	ALA3252248	F	Antimalarial activity against cycloguanil-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days	Plasmodium gallinaceum	8	ALA3244272	organism-based format	Scientific Literature
15.	ALA3252250	F	Antimalarial activity against DDS-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days	Plasmodium gallinaceum	8	ALA3244272	organism-based format	Scientific Literature
16.	ALA3252252	F	Antimalarial activity against chloroquine-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days relative to parent strain	Plasmodium gallinaceum	8	ALA3244272	organism-based format	Scientific Literature
17.	ALA3252254	F	Antimalarial activity against cycloguanil-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days relative to parent strain	Plasmodium gallinaceum	8	ALA3244272	organism-based format	Scientific Literature
18.	ALA3253631	F	Antimalarial activity against DDS-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days relative to parent strain	Plasmodium gallinaceum	8	ALA3244272	organism-based format	Scientific Literature
19.	ALA3253632	F	Antimalarial activity against chloroquine-sensitive, pyrimethamine-resistant Plasmodium falciparum Malayan Camp CH/Q infected in Aotus monkey assessed as dose required to >50% cures compound treated for 7 days	Plasmodium falciparum	9	ALA3244272	organism-based format	Scientific Literature
20.	ALA3253633	F	Antimalarial activity against chloroquine-resistant, pyrimethamine-sensitive Plasmodium falciparum Vietnam Oak Knoll in Aotus monkey assessed as dose required to >50% cures compound treated for 7 days	Plasmodium falciparum	10	ALA3244272	organism-based format	Scientific Literature